Core Insights - The article discusses the rapid growth and development of DeepMind Technology, highlighting its recent C-round financing of over 800 million RMB, leading to a valuation exceeding 6 billion RMB. The financing was supported by both existing and new investors with strong industry backgrounds [4][5][25]. Group 1: Company Background - DeepMind Technology started in 2018 with a few research papers and has since secured hundreds of millions in financing, becoming a key player in the AI for Science (AI4S) sector [5]. - The company was founded by Zhang Linfeng and his peers, who realized the potential of AI in molecular dynamics simulations, achieving results that previously required extensive computational resources [8][9]. Group 2: Key Milestones - The company won the national disruptive technology innovation competition, receiving 12 million RMB in funding, which validated their technological intuition [8]. - In 2020, the founders received the Gordon Bell Award, a prestigious recognition in high-performance computing, further enhancing their credibility and attracting investment [8]. Group 3: Talent Acquisition - The recruitment of top talent, such as AI expert Ke Guolin from Microsoft Research Asia, marked a significant turning point for the company, allowing it to scale its operations and enhance its algorithm capabilities [12][13]. - Ke Guolin's team successfully replicated Google DeepMind's AlphaFold2, becoming the first globally to achieve this feat, which significantly boosted the company's reputation in the AI4S field [14][16]. Group 4: Business Strategy - DeepMind Technology chose to focus on being a software platform rather than a biotech company, aiming to build trust with pharmaceutical clients by avoiding direct competition in drug development [19]. - The company aims to become a "Dassault Systemes of the micro-world," addressing fundamental issues in molecular research applicable across various industries, including pharmaceuticals and materials science [19]. Group 5: Super Laboratory Initiative - To bridge the gap between AI predictions and practical applications, DeepMind established a "super laboratory" to automate experimental processes, enhancing the efficiency of scientific research [21][22]. - This initiative aims to create a continuous supply of high-quality experimental data, which will feed back into AI models, forming a data flywheel that benefits the entire AI4S industry [23]. Group 6: Market Position and Future Aspirations - The recent C-round financing from state-backed institutions signals a recognition of AI4S as a strategic national infrastructure, emphasizing its importance in overcoming technological bottlenecks [25]. - Despite facing valuation pressures compared to U.S. counterparts, the company believes it can achieve a breakthrough akin to AlphaFold, which would significantly enhance its market perception and investment appeal [27].

Core Viewpoint - DeepMind's documentary "The Thinking Game" parallels the journey of DeepMind and DeepSense Technology, highlighting the intersection of AI and biological research, while emphasizing the company's recent C-round financing of over 800 million RMB, leading to a valuation exceeding 6 billion RMB [3][4]. Group 1: Company Background and Development - DeepSense Technology was founded in 2017, initially funded by a 12 million RMB award from a national innovation competition, which laid the groundwork for its future success [6][5]. - The company gained recognition in 2020 by winning the Gordon Bell Award for breakthroughs in "deep potential" molecular simulations, marking a significant milestone in its development [6][7]. - The founder, Zhang Linfeng, turned down an offer from DeepMind to lead DeepSense, emphasizing a commitment to innovation in China [7]. Group 2: Key Technological Achievements - The company successfully replicated Google DeepMind's AlphaFold 2, a significant achievement in protein modeling, under limited resources, showcasing the team's dedication and expertise [11][12]. - DeepSense chose to focus on being a software platform rather than a biotech company, aiming to establish itself as a "micro-world Dassault System," which can be applied across various industries beyond pharmaceuticals [14][15]. Group 3: Strategic Decisions and Market Position - The decision to avoid direct drug development was driven by the need to maintain trust with pharmaceutical clients, allowing DeepSense to act as a neutral third party [15]. - The establishment of a "super laboratory" aims to bridge the gap between AI predictions and practical applications, addressing the challenge of data scarcity in AI for Science [17][18]. Group 4: Funding and Market Dynamics - The recent C-round financing included state-backed institutions, indicating that AI for Science is now viewed as a strategic national research infrastructure [21][20]. - Despite the potential, Chinese AI for Science companies face valuation pressures compared to their U.S. counterparts, with a need for a breakthrough project akin to AlphaFold to gain investor confidence [23][22]. Group 5: Philosophical Considerations - The founders of DeepSense reflect on the ethical implications of AI, recognizing the potential for AI to surpass human intelligence and the importance of maintaining human values in the face of technological advancement [25][26].